Affordable Access

Publisher Website

Osteonecrosis and Bisphosphonates in Oral and Maxillofacial Surgery

Authors
Publisher
Elsevier Inc.
Publication Date
Volume
19
Issue
2
Identifiers
DOI: 10.1016/j.coms.2007.01.005
Disciplines
  • Medicine

Abstract

Bisphosphonates are a class of compounds approved for the treatment of multiple myeloma, hypercalcemia of malignancy, osteolytic lesions of metastatic disease, Paget's disease, and most commonly, osteoporosis. Recently, these drugs have been associated with a new clinical entity, bisphosphonate related osteonecrosis (BRON) which is characterized by jaw necrosis that typically presents following dentoalveolar surgery. The pathogenesis for this complication appears to related to bisphosphonate mediated inhibition of osteoclast function and normal bone remodeling. This complication can have a significant impact on the quality of life for those patients with advanced stages of necrosis.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Osteonecrosis and bisphosphonates in oral and maxi...

on Oral and maxillofacial surgery... May 2007

Advantages and disadvantages of the use of bisphos...

on International dental journal August 2010

Lack of association between oral bisphosphonates a...

on Osteoporosis International Jun 01, 2008
More articles like this..